• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Displaying 114-128 of 145 results

1004 Exhibit: Part 4 ¿¿¿ Pages 1051 1400 File History for ¿¿¿546 Patent, Ser No 13495,942 ¿¿¿546 FH

Document IPR2019-00450, No. 1004-3 Exhibit - Part 4 ¿¿¿ Pages 1051 1400 File History for ¿¿¿546 Patent, Ser No 13495,942 ¿¿¿546 FH (P.T.A.B. Jan. 29, 2019)
The term "heteroaryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyroy!, thienyl, isothiazoly!, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinoly:, benzofuryl, isobenzofury!, benzothieny!, pyrazolyl, indoiyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazoly!, oxazolyl, benzthiazoly!
The presentinvention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting ofarthritis, osteoporosis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID'S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic AQUESTIVE EXHIBIT 1004=page 1056 AQUESTIVE EXHIBIT 1004 page 1056
Solid compositions of a similar type may also be employedasfillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
intravenous use) a sterile injectable solution of the active ingredient Salutions of a therapeutic compoundof the present invention in either sesame or peanutoil orin aqueous propylene glycol may be employed.
)propionicacid A solution of (2S)-2-hydroxy-3-(4-methoxybenzenesulfonyl)propionic acid benzyl ester (1.0 grams, 2.8 mmole) in methanol (70 mL) wastreated with 10% palladium on activated carbon (100 mg) and hydrogenated at 3 atmospheres pressure for 3 hours in a Parr shaker.
cite Cite Document

1024 Exhibit: Osborne et al, Skin Penetration Enhancers Cited in the Technical Literature, Pharmaceutical Technology, November 1997 Osborne

Document IPR2019-00450, No. 1024 Exhibit - Osborne et al, Skin Penetration Enhancers Cited in the Technical Literature, Pharmaceutical Technology, November 1997 Osborne (P.T.A.B. Jan. 29, 2019)
Al- though recent efforts in using chemical enhancers have fo- cused on substances categorized as generally recognized as safe (GRAS), early work included a wide range of materi- als.
Additives that en- hance skin delivery by altering solubility of the active ingredi- ent in the formulation (including supersaturation) or by opti- AQUESTIVE EXHIBIT 1024 page 0002
Penetration of Guinea Pig Skin by Acyclovir in Different Vehicles and Correlation with the Efficacy of Topical Therapy of Experimental Cutaneous Herpes Simplex Virus Infection.
Effect of Azone and Propylene Glycol on Penetration of Trifluorothymidine Through Skin and Efficacy of Different Topical Follnulations Against Cutaneous Herpes Simplex Virus Infections in Guinea Pigs.
Effect of Penetration Enhancers on the in vitro Transport of Ephedrine Through Rat Skin and Human Epidermis from Matrix Based Trans dermal Foi inulations .
cite Cite Document

1029 Exhibit: O¿¿¿Dell et al, School nurses¿¿¿ experience with administration of rectal diazepam gel for seizures, J Sch Nurs, June 2007, 233166 9 O¿¿¿Dell

Document IPR2019-00450, No. 1029 Exhibit - O¿¿¿Dell et al, School nurses¿¿¿ experience with administration of rectal diazepam gel for seizures, J Sch Nurs, June 2007, 233166 9 O¿¿¿Dell (P.T.A.B. Jan. 29, ...
Perceived Barriers to Diazepam Rectal Gel Administration in the School Perceived Barrier Number Privacy/setting Access/availability of nurse Legal/delegation issues Staff anxiety/fear Lack of training None Consent of ...
cite Cite Document

1003 Exhibit: US Patent No 8,895,546, Administration Of Benzodiazepine Compositions, filed June 13, 2012 ¿¿¿546 Patent

Document IPR2019-00450, No. 1003 Exhibit - US Patent No 8,895,546, Administration Of Benzodiazepine Compositions, filed June 13, 2012 ¿¿¿546 Patent (P.T.A.B. Jan. 29, 2019)
In some embodiments, the benzodiazepine drug is selected from the group consisting of: alprazolam, brotizolam, chlordiaz- epoxide, clobazam, clonazepam, clorazepam, demox- azepam, diazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam, oxazepam, lorazepam, prazepam, quazepam, triazolam, temazepam, loprazolam, any pharmaceutically-acceptable salts thereof, and any combinationsthereof.
In some embodiments, the benzodiazepine drug is selected from the group consisting of alprazolam, brotizolam, chlor- diazepoxide, clobazam, clonazepam, clorazepam, demox- azepam, diazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam, oxazepam, lorazepam, prazepam, quazepam, triazolam, temazepam, loprazolam, any pharmaceutically-acceptable salts thereof, and any combinationsthereof.
In some embodiments, the benzodiazepine drug is selected from the group consisting of alprazolam, brotizolam, chlor- diazepoxide, clobazam, clonazepam, clorazepam, demox- azepam, diazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam, oxazepam, lorazepam, prazepam, quazepam, triazolam, temazepam, loprazolam, or any pharmaceutically-acceptable salts thereof, and any combinationsthereof.
In some embodiments, the benzodiazepine drug is selected from the group consisting of alprazolam, brotizolam, chlor- diazepoxide, clobazam, clonazepam, clorazepam, demox- azepam, diazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam, oxazepam, lorazepam, prazepam, quazepam, triazolam, temazepam, loprazolam, any pharmaceutically-acceptable salts thereof, and any combinationsthereof.
In some embodiments, the benzodiazepine drug is selected from the group consisting of alprazolam, brotizolam, chlor- diazepoxide, clobazam, clonazepam, clorazepam, demox- azepam, diazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam, oxazepam, lorazepam, prazepam, quazepam, triazolam, temazepam, loprazolam, or any pharmaceutically-acceptable salts thereof, and any combinationsthereof.
cite Cite Document

1007 Exhibit: Part 2 ¿¿¿ Pages 401 800 File History for Non Provisional Patent Application Serial No 12413,439, filed March 27, 2009 ¿¿¿439 FH

Document IPR2019-00450, No. 1007 Exhibit - Part 2 ¿¿¿ Pages 401 800 File History for Non Provisional Patent Application Serial No 12413,439, filed March 27, 2009 ¿¿¿439 FH (P.T.A.B. Jan. 29, 2019)
For compounds ofthe formula NRRoR3Ru™: (i) none of R ...
Priority under 35 U.S.C. § 119 12)L] Acknowledgmentis made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or(f). a)LJAll b)L ] Some*c)L] Noneof: 1.L] Certified copies of the priority documents have been received.
AQUESTIVE EXHIBIT 1007 AQUESTIVE EXHIBIT 1007 page 0450 page 0450 Application/Control Number: 12/413,439 Art Unit: 1612 Page 4 All claims directed to a nonelected process invention must require all the limitations of an ...
Priority under 35 U.S.C. § 119 12)[] Acknowledgmentis made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)L] All b)L ] Some * c)L] None of: 1.) Certified copies of the priority documents have been received.
Claims 1-19 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.
Indeed, consistent with Sonne’s general teaching at column3, lines 65- 67, none of the Examples taught by Sonne suggest nasal administration of a benzodiazepine drug formulation that contains only tocopherol or tocotrienol, a alcohol ...
... EXHIBIT 1007 AQUESTIVE EXHIBIT 1007 page 0501 page 0501 Application No. 12/413,439 Response to March 18, 2011 Office Action Attorney Docket No.: 35401-716.201 This teaching away is underscoredbythe fact that none ...
... teaching at column3, lines 65-67, none of the Examples taught by Sonne suggest nasal administration of a benzodiazepine drug formulation that contains only tocopherol or tocotrienol, a alcohol and optionally an alkylglcoside. And none ...
cite Cite Document
+ More Snippets

1010 Exhibit: US Patent Application Publication No US 20090258865, Administration of Benzodiazepine Compositions, Serial No 12413,439 Cartt¿¿¿865

Document IPR2019-00450, No. 1010 Exhibit - US Patent Application Publication No US 20090258865, Administration of Benzodiazepine Compositions, Serial No 12413,439 Cartt¿¿¿865 (P.T.A.B. Jan. 29, 2...
In some embodiments, the composition consists essentially of a benZodiaZepine drug that is fully dissolved in a solvent con sisting of one or more natural or synthetic tocopherols or tocotrienols, one or more alcohols or glycols, and optionally one or more alkyl glycosides Wherein the solution is at least substantially free of Water.
In some embodiments, the composition consists essentially of a benZodiaZepine drug that is fully dissolved in a solvent con sisting of one or more natural or synthetic tocopherols or tocotrienols, one or more alcohols or glycols, and optionally one or more alkyl glycosides.
In some embodiments, the composition con sists of a benZodiaZepine drug in a form including benZodi aZepine microparticles and/or nanoparticles suspended in a carrier system consisting of Vitamin E TPGS, methylparaben, propylparaben, propylene glycol, povidone and Water.
[0049] In some embodiments, the composition contains a benZodiaZepine drug that at least partially in a particulate form suspended in a carrier system containing a natural or synthetic tocopherol or tocotrienol, one or more alcohols or glycols, and an alkyl glycoside.
In some embodiments, benzo diazepine comprises a member of the group consisting of alprazolam, diazepam, ?urazepam, lorazepam, medazepam, mexazolam, midazolam, temazepam and pharmaceutically acceptable salts and combinations thereof.
cite Cite Document

1017 Exhibit: Cartt et al, WO 2008137960, Nasal Administration Of Benzodiazepines, published November 13, 2008, International filing date May 7, 2008 PCTUS2008062961 Cartt ¿¿¿960

Document IPR2019-00450, No. 1017 Exhibit - Cartt et al, WO 2008137960, Nasal Administration Of Benzodiazepines, published November 13, 2008, International filing date May 7, 2008 PCTUS200806296...
In some embodiments, the nanoparticulate benzodiazepine particles comprise at least one member of the group consisting of alprazolam, diazepam, flurazepam, lorazepam, medazepam, mexazolam, midazolam, temazepam and pharmaceutically acceptable salts and combinations thereof.
In some embodiments, the nanoparticulate benzodiazepine particles comprise at least one member of the group consisting of alprazolam, diazepam, flurazepam, lorazepam, medazepam, mexazolam, midazolam, temazepam and pharmaceutically acceptable salts and combinations thereof.
In some embodiments, the benzodiazepine drug comprises at least one member ofthe group consisting of alprazolam, diazepam, flurazepam, lorazepam, medazepam, mexazolam, midazolam, temazepam and pharmaceutically acceptable salts and combinations thereof.
In some embodiments, the nanoparticulate benzodiazepine particles comprise at least one member of the group consisting of alprazolam, diazepam, flurazepam, lorazepam, medazepam, mexazolam, midazolam, temazepam and pharmaceutically acceptable salts and combinations thereof.
In some embodiments, the nanoparticulate benzodiazepine particles comprise at least one member of the group consisting of alprazolam, diazepam, flurazepam, lorazepam, medazepam, mexazolam, midazolam, temazepam and 1 5 pharmaceutically acceptable salts and combinations thereof.
cite Cite Document

1022 Exhibit: Liversidge et al, US Patent Application Publication No US 20060198896, Serial No 11354,249, published September 7, 2006 Liversidge

Document IPR2019-00450, No. 1022 Exhibit - Liversidge et al, US Patent Application Publication No US 20060198896, Serial No 11354,249, published September 7, 2006 Liversidge (P.T.A.B. Jan. 29, 201...
HoWever, none of these documents describe aerosols of a nanoparticulate benZodiaZepine, such as loraZepam.
... compositions of nanoparticulate drugs include US. Pat. No. 6,153,225 for “Injectable Formulations of Nanoparticulate Naproxen,” and US. Pat. Nos. 5,399,363 and 5,494,683, both for “Surface Modi?ed Anticancer Nanoparticles.” None ...
For com pounds of the formula NR1R2R3R4(+): [0113] (i) none of R1-R4 are CH3 ...
cite Cite Document

1028 Exhibit: Ivaturi et al, Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers, Acta Neurol Scand 2009 Nov1205353 7 doi 101111j1600 0404200901170x Epub 2009 May 14 Ivaturi

Document IPR2019-00450, No. 1028 Exhibit - Ivaturi et al, Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers, Acta Neurol Scand 2009 Nov1205353 7 doi 1...
Nonetheless, some patients and caretakers would prefer the transient discomfort of the present i.n. formulations to rectal administration of medica- tion in public settings.
cite Cite Document

1007 Exhibit: Part 5 ¿¿¿ Pages 1601 2000 File History for Non Provisional Patent Application Serial No 12413,439, filed March 27, 2009 ¿¿¿439 FH

Document IPR2019-00450, No. 1007-5 Exhibit - Part 5 ¿¿¿ Pages 1601 2000 File History for Non Provisional Patent Application Serial No 12413,439, filed March 27, 2009 ¿¿¿439 FH (P.T.A.B. Jan. 29, 2019)
Slovenia Slovakia Senegal Swaziland Chad Togo Tajikistan Turkmenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan Viet Nam Yugoslavia Zimbabwe
The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluoro, chloro, cyano, nitro, trifluoromethyl, (C,-C,)alkoxy, (C,-C, .
The term "heteroaryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, suchas pyridyl, furyl, pyrroyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryi, benzothienyl, pyrazolyl, indolyl, isoindoly!l, purinyi, carbazolyl, isoxazolyl, thiazolyi, oxazolyl, benzthiazolyl or benzoxazolyl, optionally substituted by 1 to 2 substituents independently selected from the group consisting of fluoro, chloro, trifluoromethyl, (C,- C,)alkoxy, (C,-C,,)aryloxy,trifluoromethoxy, difluoromethoxy and (C,-C,)alkyl.
The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammai an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
Solid compositions of a similar type may also be employed asfillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
cite Cite Document

1035 Exhibit: Davis, Delivery of peptide and non peptide drugs through the respiratory tract, Pharmaceutical Science Technology Today, Vol 2, No 11 November 1999, pages 450 456 Davis

Document IPR2019-00450, No. 1035 Exhibit - Davis, Delivery of peptide and non peptide drugs through the respiratory tract, Pharmaceutical Science Technology Today, Vol 2, No 11 November 1999, pag...
Although the surface area of the nose is not as large as that found in the lung, it does provide an effective site for the efficient systemic absorption of many conven- tional drugs, and particularly those compounds that are relatively water soluble but also lipophilic in nature (as shown by their partition- ing properties)1.
Indeed, recent studies performed in Japan and the United States would suggest that, almost invariably, the high bioavailabilities achieved with absorption enhancers for the delivery of polar compounds across mucosal membranes can be associated with tissue damage11.
It has been demonstrated that this chitosan ef- fect with various polypeptides, that include desmopressin, in- sulin, leuprolide, calcitonin, PTH, CCK-8, as well as with polar compounds for the treatment of migraine, such as alniditan, and analgesic agents such as morphine.These studies have been performed in an ovine model and in man4.
It would appear that inhalation systems – pulmonary or nasal – may soon be in development for cannabinoid delivery as part of a drive in the UK to establish whether these compounds could provide benefit in the treat- ment of pain and other conditions such as multiple sclerosis.
Update– latest news and views Adenosine receptors as potential therapeutic targets Sonya M. Kaiser and Ronald J. Quinn Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond Shaker A. Mousa Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination Margaret F. Taylor, Kristin Wiederholt and Fran Sverdrup Monitor– new bioactive molecules, combinatorial chemistry, invited profile In the December issue of Pharmaceutical Science & Technology Today… Update– latest news and views Synthesis and applications of novel highly efficient HPLC chiral stationary phases: a chiral dimension in drug research analysis G. Cancelliere, I. D’Acquarica, F. Gasparrini, D. Misti and C. Villani Aging processes in pharmaceutical polymers J-H. Guo Pegylated liposomal adriamycin: a review of current and future applications S. Stewart and C. Lewanski Monitor– drug delivery and analytical techniques AQUESTIVE EXHIBIT 1035 page 0007
cite Cite Document

1014 Exhibit: Gwozdz et al, WO 2009120933, Pharmaceutical Solutions And Method For Solubilizing Therapeutic Agents, published October 1, 2009, International Filing Date March 27, 2009 PCTUS2009038518 Gwozdz

Document IPR2019-00450, No. 1014 Exhibit - Gwozdz et al, WO 2009120933, Pharmaceutical Solutions And Method For Solubilizing Therapeutic Agents, published October 1, 2009, International Filing Da...
Exemplary hydrophobic or lipophilic therapeutic agents which can be solubilized in accordance with the present invention include, but are in no way limited to, steroids such as Dexamethasone, 17-beta-Estradiol; benzodiazepenes such as Diazepam, alpraxolam, bromazepam, chlordiazepoxidem, clonazepam, estazolam, flunitrazepam, flurazepam, lorazepam, lormetazepam, mexazolam, nitrazepam, oxazepam, temazepam, and triazolam; Rapamycin and analogues; Taxol (paclitaxel) and analogues; Actinomycin D; Prostaglandins (PGEl); Vitamin A; Probucol; Batimastat; Statins (HMG-CoA Reductase Inhibitors; Trapidil (and other anti-proliferative Growth Factor Inhibitors); Cytochalasin B; and microtubule binding agents such as epothilones, elutherobin and discodermolide.
Specifically, pharmaceutical compositions of the present invention can be administered by any of the following nonlimiting exemplary routes, intraabdominal, intraarterial, intraarticular, intracapsular, intracervical, intracranial, intraductal, intradural, intralesional, intralocular, intralumbar, intramural, intranasal, intraocular, intraoperative, intraparietal, intraperitoneal, intrapleural, intrapulmonary, intraspinal, intrathoracic, intratracheal, intratympanic, intrauterine, and intraventricular.
In addition, the instant pharmaceutical solution can be formulated into sustained-release preparations and devices including, but not limited to, those relying on osmotic pressures to obtain a desired release profile.
Formulations suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
Formulations suitable for transdermal administration can also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6) :318 ( 1986)) and typically take the form of an optionally AQUESTIVE EXHIBIT 1014 page 0012
cite Cite Document

1038 Exhibit: Bara, US Patent Application Publication No US20060178290, Serial No 10563,967, published August 10, 2006 Bara

Document IPR2019-00450, No. 1038 Exhibit - Bara, US Patent Application Publication No US20060178290, Serial No 10563,967, published August 10, 2006 Bara (P.T.A.B. Jan. 29, 2019)
[0003] Ethanol constitutes a good solubilizing agent for perfuming ingredients, and additionally has the advantage of being inexpensive and of alloWing the formulation of trans parent compositions.
[0005] A ?rst route consists in replacing ethanol With aqueous compositions containing hydrophilic solubilizing agents such as polyethoxylated hydrogenated castor oils.
Moreover, the presence of Water in a large quantity is capable of causing degradation of the perfuming ingredients over time and therefore of adversely affecting the olfactory characteristics of the product.
[0006] Another solution further consisted in providing perfume compositions in Which the ethanol is at least partially replaced by one or more volatile silicones Which are lineariof the polydimethylsiloxane type4or cyclic.
[0007] HoWever, the applicant has noW discovered, sur prisingly, that by choosing a particular combination of silicone compounds not described in the prior art, it Was possible to obtain a perfume composition Whose rate of evaporation is close to that of ethanol and possessing a ?ash point greater than or equal to 00 C., preferably greater than or equal to 10° C. [0008] The subject of the present invention is therefore a perfume composition comprising a mixture of fragrant mate rials in a physiologically acceptable carrier comprising a mixture of polydimethylsiloxanes, characterized in that the said mixture of polydimethylsiloxanes consists of hexam ethyldisiloxane and octamethyltrisiloxane in a hexamethyl disiloxane to octamethyltrisiloxane Weight ratio ranging from 30:70 to 70:30.
cite Cite Document

1015 Exhibit: Cartt et al, US Patent Application Publication No US 20080279784, Nasal Administration Of Benzodiazepines, Serial No 12116,842, published November 13, 2008 Cartt ¿¿¿784

Document IPR2019-00450, No. 1015 Exhibit - Cartt et al, US Patent Application Publication No US 20080279784, Nasal Administration Of Benzodiazepines, Serial No 12116,842, published November 13, 2...
In some embodiments, the nanoparticulate benZodiaZepine particles comprise at least one member of the group consisting of alpraZolam, brotiZolam, chlordiaZepoxide, clobaZam, clon aZepam, cloraZepam, demoxaZepam, ?umaZenil, ?uraZepam, halaZepam, midaZolam, nordaZepam, medaZepam, diaZ AQUESTIVE EXHIBIT 1015 page 0006
In some embodiments, the nanoparticulate benZodi aZepine particles comprise at least one member of the group consisting of alpraZolam, diaZepam, ?uraZepam, loraZepam, medaZepam, mexaZolam, midaZolam, temaZepam and phar maceutically acceptable salts and combinations thereof.
In some embodiments, the benZodiaZepine particles comprise at least one member of the group consist ing of alpraZolam, diaZepam, ?uraZepam, loraZepam, medaZepam, mexaZolam, midaZolam, temaZepam and phar maceutically acceptable salts and combinations thereof.
In some embodiments, the nanoparticulate benZodiaZepine particles comprise at least one member of the group consisting of alpraZolam, diaZepam, ?uraZepam, loraZepam, medaZepam, mexaZolam, mida Zolam, temaZepam and pharmaceutically acceptable salts and combinations thereof.
In some embodiments, the nanoparticulate benZodiaZepine particles comprise at least one member of the group consisting of alpraZolam, diaZepam, ?uraZepam, loraZepam, medaZepam, mexaZolam, mida Zolam, temaZepam and pharmaceutically acceptable salts and combinations thereof.
cite Cite Document

1040 Exhibit: Part 2 Pages 251 500 File History for EP 128 013729, based on WO 2012174158 and PCTUS2012042311

Document IPR2019-00450, No. 1040-2 Exhibit - Part 2 Pages 251 500 File History for EP 128 013729, based on WO 2012174158 and PCTUS2012042311 (P.T.A.B. Jan. 29, 2019)
... citations and explanations supporting such statement Statement Novelty (N) Inventive step (1S) Industrial applicability (IA) Claims Claims 9-12, 32-35 1-8, 13-31, 36-62 Claims Claims Claims Claims NONE 1-62 1-62 NONE ...
Nonetheless, social objections by older children and adults and legal concerns about rectal adminis- tration havelimited its use.
... (hours) Figure 2 Mean (+standard deviation) plasma concentration—timeprofiles of diazepam after intravenous and intranasal adminis- tration in twenty-four subjects (semi-logarithmic scale). criteria of a serious adverse event, and none ...
Noneof the cited documents discloses a pharmaceutical solution having a composition as definedin claim 1 for nasal administration for treating seizures.
Noneofthe cited prior art documents teaches that an improved treatment of seizures can be achieved when using a combination of ethanol and benzy! alcoholin a nasal pharmaceutical solution comprising a benzodiazepine drug.
... 0322 page 0322 TA eeeName: Galvez, Joélle European Patent Office Postbus 5818 2280 HV Rijswijk NETHERLANDS Tel: +31 70 340 2040 Fax: +31 70 340 3016 Tel: +31 70 340 - 2434 or call +31 (0)70 340 45 00 . . NoneGamerGalarde, ...
Indeed, consistent with Sonne’s general teaching at column 3, lines 65-67, none of the Examples taught by Sonne suggest nasal administration of a benzodiazepine drug formulation that contains only tocopherol or tocotrienol, an ...
None of the six volunteers had local irritation of the nostrils 30 minutes after application, see table 2.
cite Cite Document
+ More Snippets
<< 1 2 3 4 5 ... 8 9 10 11 >>